Continuous Glucose Monitoring in Dialysis Patients With Diabetes

Launched by BO FELDT-RASMUSSEN · Oct 11, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how effective continuous glucose monitoring (CGM) is for patients with diabetes who are undergoing dialysis. The goal is to see if using CGM, either continuously or intermittently, can help improve blood sugar control compared to standard methods that involve finger-prick tests and blood tests every few months. Participants will be monitored for nine months and divided into three groups: one group will receive regular standard monitoring, another will have access to CGM at certain times, and the third group will have CGM available continuously throughout the study.

To join the trial, participants need to be between 65 and 74 years old, have type 1 or type 2 diabetes, and be on dialysis for at least two weeks. They should also be able to read and understand either Danish or English. Throughout the study, participants will meet with a specialist who will help adjust their diabetes medications as needed. This trial aims to find out how well these monitoring methods work for managing diabetes in dialysis patients and whether they can lead to better health outcomes overall.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Written informed consent obtained before any trial-related procedures are performed
• • Diabetes, one of the following groups: Type 1 diabetes OR Type 2 diabetes receiving glucose-lowering therapy OR Type 2 diabetes managed with lifestyle changes with an HbA1c ≥ 50 mmol/mol
• • Maintenance haemodialysis or peritoneal dialysis (minimum of two weeks)
• • Subject must be willing and able to comply with trial protocol and be fluent in Danish or English
• Exclusion Criteria:
• • Major allergy to tape/adhesives
• • Women who are pregnant or planning pregnancy
• • Ongoing use of CGM
• • Ongoing use of insulin pump